The FDA approved Ultomiris (ravulizumab) injection for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease.
FDA approves new treatment for adult patients with rare, life-threatening blood disease
More from FDA News AlertsMore posts in FDA News Alerts »
- Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
- Armstrong Medical Limited Recalls AMSORB PLUS PREFILLED G-CAN 1.0L Due to Reduced Gas Flow to Patients During Anesthesia
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices